Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
These institutions hold a total of 3,164,315 shares.
Total shares in issue = 255m
Or 255,000,000
This is about 1.25% of the company. This is a small percentage.
I don’t know the point you are trying to make. Is it likely that they will double their shareholding if there is a USA listing?
Will it attract American buyers? Will the share price rise because of an American listing? Do the Americans not trust the UK’s FT-100? FT-250 .. or the AIM?
I don’t think that means that the share price will double. Maybe the SP will rise 5%. Maybe it will not.
Dox as a drug has proven efficacy to some extent.. but at some substantial/sacrificial cost to the patient's health and so the drug is restricted/limited to healthy/young patients. Those patients whose health is compromised, will not get to have a go.. until now. And so the market size will dramatically increase. I think checking the FAP activity prior to AVA6K dosage is the key. There is no point in overloading the tumour with Deoxrubin that it cant process/assimilate into its DNA .. Think of Goldilocks and the 3 bears; i.e. Not too hot, too cold, but just right. This will differ for different patients. In this patient's tailor-fit approach; matching the dosage to the tumour size/type and FAP activity will be key to AVA6K's success. I don't think anybody will touch this...
Ophidian's comment ..
I think you are confusing Safety and Efficacy
Yes, they have already demonstrated it is safe to use.
I think they are trying to adapt the methodology of altering the dose to match FAP activity to improve efficacy.
If it is released in the tumour, but not assimulated (used), then presumably it will be washed out to cause havoc to the healthy cells. They won't want that. The biopsy tumour data will confirm. They will be trying to establish what the FAP activity is present before dosing and adjust the dose accordingly so that the tumour can assimilate ALL the Deoxrubin into the DNA where it will do the necessary damage. I suspect that is why Avacta is doing research on determining the FAP activity prior to dosing so that they can treat it more effectively. This will be a patient/tumour-dependent approach. There is no point in overloading. The benefit of chem with no side effects is massive and it will come good. I liken it to a recipe. You just need to add the right ingredients at the right time, in the right quantity. It takes practice/experience to get it right. Avacta is unlikely to hit the 'sweet spot' first time every time. We are not that lucky. Research takes time to get it right... The biopsy tumour data will confirm how far away they are... which is why I think they are delaying the release of biopsy data as they will need to make adjustments and repeat.
I am waiting for SP to reach £20 before I sell ... I have a long way to go. I like to think I am patient, but I am not. It all depends on how well the news is received by the cancer-treating community. It doesn't get much better than chemo without any side effects... and so I am expecting a massive re-rate and hopefully, very soon a bidding war ensues... With any re-rate, I think it would be madness to sell.. unless you were profit taking and re-buying.
well the US brokers will be lining up!!
When will it KO?
Slow burn .. I was hoping somebody would light the blue touch paper
(Touch paper is a strip of paper treated with potassium nitrate that is used as a fuse for explosives.)
It's been over 18 months .. ow since I have been addicted to Avacta...
When is when??? I am trying to be very patient, but it is hard. I guess I am still a kid.
I have not read the T&Cs, but as I understand, these companies that have bought license deals are not permitted to buy shares in the company more than 5% and are not permitted s T/O or BO ..
The disaster that Porton messed up, as did the managing team for the gov. process…. a disgrace.
Almost corrupt .. Frozen Pigs Spit. They knew that this process would f**k up the performance test. Who uses Frozen Pig SPit??
Also, to give the Chinese test a bye, so that they did not have to pass the test .. def corrupt. ..
Let us move on and not look backwards.
Interesting.
Will there be a link to follow this presentation??
Good post...
I agree with all of the above. But this information has not (yet) translated into the SP and so it presents a great buying opportunity. I have maxed out and now waiting very patiently for the first big inflexion points in September/Q3 2022... which is not that too long away. I think over the next two years, there will be multiple inflexions .. I am looking forward to it.
when, next week, next month, next year?
Where did you buy your crystal ball??
Is this a $4B fundraise? I am confused?
Is this Point, Bio Point? Did I read Avacta own a 25% stack in the POINT’s CanSEEKTM technology? under a licensing deal?
Silly question
But how does anybody KNOW who (say Blackrock) is buying and by how much... I think this is guess work.
Does Avacta really want to be taken over? I thought they would make more money by licencing the platform to other Pharmas using different drugs .. and collecting royalties a % of the t/o. The slope to riches would not be very steep, but the height (the total profits) of the mountain would be significantly bigger as more than one Pharma can take a slice. Whatever happens, I would like the company to be British and pay UK taxes.
Am I being a sentimentalist? Too Nationalistic maybe? So long as the Chinese don't get their filthy paws on it.
Am I mean to think (and say/write a meassage) that
Looking (I used as search on the ASCO website for the Annual Meeting) and it came up as a zero response
0 Results for "avacta"
Did you mean acaca instead of "avacta"?
I am concerned and I was NOT expecting that :-(
Will AVACTA be presenting another poster or something ..??? I am confused.
Stodgy88; how do you know that black rock purchased 1%??
I am curious to learn.